Newsroom

Press Release
Minaris Regenerative Medicine and VectorBuilder Collaborate to Accelerate Therapeutic Breakthroughs
VectorBuilder, a global leader in gene delivery technologies, is thrilled to announce its partnership with Minaris Regenerative Medicine (Minaris), a leading contract development and manufacturing organization (CDMO) focusing on cell and gene therapies (CGT). This strategic collaboration aims to leverage VectorBuilder’s integrative know-how on GMP vector manufacturing and Minaris’s extensive CGT manufacturing track records to further advance comprehensive solutions for customers in need of cutting-edge CGT development. Read More ››
Press Release
VectorBuilder Leverages Danaher Solutions to Advance Gene Delivery Technologies
VectorBuilder, a global leader in gene delivery technologies, is pleased to announce it will utilize strategic new capabilities from global life sciences and diagnostics innovator Danaher Corporation to advance scientific research and clinical applications in the gene delivery industry to improve human health. Read More ››
Press Release
Cambodian Deputy Prime Minister SUN Chanthol Visits VectorBuilder to Explore the Collaboration in the Medical and Health Sector
Cambodian Deputy Prime Minister and First Vice Chairman of Council for the Development of Cambodia (CDC), SUN Chanthol, along with senior government officials from entities including the Foreign Trade Bank and the Investment Committee, conducted an official visit to VectorBuilder’s R&D and manufacturing base in Guangzhou, China. Read More ››
Press Release
VectorBuilder Japan Launches Gene Therapy Pilot Program for Rare Disease Menkes in Japan
VectorBuilder Japan is thrilled to announce the inclusion of its collaborative initiative, the "Menkes Rare Pediatric Disease Clinical Research Pilot Program," in the Japan External Trade Organization's (JETRO) subsidy program for foreign direct investment. In partnership with Lantu Biopharma, Teikyo University, and Teikyo Heisei University, VectorBuilder brings its extensive expertise in rapid gene therapy development, production, and quality control to further explore gene therapy technologies for treating Menkes disease. Read More ››
Press Release
Recent Cash Injection Boosts VectorBuilder to Unicorn Status
Gene delivery technologies are turning into the next big-ticket item globally, as the most recent investment received by VectorBuilder Inc., a global leader in this field, from multiple venture capital firms has shown. The latest cash injection builds on the $57 million Series C funding completed in November last year, which brings the total amount raised to date to just over $76 million and propels the organization to unicorn status with over $1 billion valuation. Read More ››
Press Release
VectorBuilder Establishes Second Office in Kobe, Japan, Advancing Global Expansion
VectorBuilder, a leading company specializing in gene delivery technology, is pleased to announce the establishment of its second subsidiary in Japan, located in Kobe Medical Industry City. This milestone follows the successful opening of the Yokohama office, marking VectorBuilder's commitment to advancing its global presence and fostering innovative collaborations within the Japanese biopharmaceutical industry. Read More ››
Press Release
VectorBuilder Expands Global Reach with UK Headquarters
VectorBuilder, a global leader in gene delivery technologies, today announced the opening of a new office in Edinburgh. This strategic expansion aims to bolster its presence in the United Kingdom and enhance the organisation’s ability to serve a region that represents one of its strongest customer bases. Read More ››
Press Release
VectorBuilder Orders Soared by 70% in 2022
VectorBuilder registered an impressive 70% YOY increase in its total orders for 2022, continuing the remarkable growth momentum of the past six years where orders have been rising 70-90% annually. Read More ››
Press Release
Again! VectorBuilder grabs top prize in major innovation competition
VectorBuilder Inc. - a global leader in gene delivery technologies - raked in another championship in the 11th China Innovation & Entrepreneurship Competition held in Shenzhen, China. This award came on the heels of the company’s top prize in the 7th “Chuangke Innovation and Entrepreneurship Global Competition” held in Hangzhou, China in November, 2022. Read More ››
Press Release
VectorBuilder won first prize in major innovation competition
VectorBuilder Inc. – a global leader in gene delivery technologies – announced that its R&D and manufacturing center in Guangzhou won championship in the 7th “Chuangke Innovation and Entrepreneurship Global Competition” held in Hangzhou, China. Read More ››
Press Release
VectorBuilder raised $57 million for gene delivery R&D
VectorBuilder Inc. – a global leader in gene delivery technologies – recently announced the completion of $57 million funding, which was co-led by Legend Capital. The fund will support the construction of VectorBuilder’s new Gene Delivery Research and Manufacturing Campus, and further boost the company’s R&D capabilities and global business presence. Read More ››
Press Release
VectorBuilder supports first gene therapy trial for Menkes disease
VectorBuilder Inc. – a global leader in gene delivery technologies – has announced that its partnership with cell and gene therapy company Lantu Biopharma has led to the first human trial of an innovative gene therapy drug candidate for Menkes disease. Read More ››
Press Release
Stand Up Therapeutics signed with VectorBuilder for world’s first gene therapy supply for paraplegia patient
Stand Up Therapeutics Co., Ltd, located in South Korea, is a gene therapy company for paralyzed patients with spinal cord injury. Stand Up Therapeutics announced on July 21 that it had signed an agreement with VectorBuilder Inc., a global leader in gene delivery solutions, to manufacture a GMP grade gene delivery system. Read More ››
Press Release
VectorBuilder to invest $30 million to build the world’s first ‘AAV Superbank’
VectorBuilder has announced its plan to invest $30 million to build an ‘AAV Superbank’ for the research and drug discovery community. Read More ››
Press Release
VectorBuilder to Expand with $500 Million ‘Gene Delivery Research and Manufacturing Campus’
VectorBuilder Inc. – a global leader in gene delivery solutions – has announced the construction of a new R&D and manufacturing center in Guangzhou, China. The ‘Gene Delivery Research and Manufacturing Campus’ will significantly expand VectorBuilder’s R&D capabilities and its production capacity for both research-use and cGMP-grade gene delivery vectors, allowing the company to continue supporting groundbreaking research worldwide. Read More ››
Please let us know what you would like to hear from us about the latest technologies or discoveries by leaving a feedback or contacting us.
Design My Vector Request Design Support